{
    "id": 4934,
    "fullName": "NOTCH1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH1 over exp indicates an over expression of the Notch1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4851,
        "geneSymbol": "NOTCH1",
        "terms": [
            "NOTCH1",
            "AOS5",
            "AOVD1",
            "hN1",
            "TAN1"
        ]
    },
    "variant": "over exp",
    "createDate": "04/16/2015",
    "updateDate": "09/26/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7155,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).",
            "molecularProfile": {
                "id": 4730,
                "profileName": "NOTCH1 over exp"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6112,
                    "pubMedId": null,
                    "title": "Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C42.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4730,
            "profileName": "NOTCH1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 13999,
                    "name": "NOTCH1 Antibody",
                    "profileName": "NOTCH1 over exp"
                },
                {
                    "id": 13997,
                    "name": "Gamma secretase inhibitor",
                    "profileName": "NOTCH1 over exp"
                },
                {
                    "id": 14000,
                    "name": "NOTCH1 Inhibitor",
                    "profileName": "NOTCH1 over exp"
                },
                {
                    "id": 13998,
                    "name": "NOTCH Inhibitor (Pan)",
                    "profileName": "NOTCH1 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}